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1. Behavioral pharmacology
Behavioral pharmacology is a multidisciplinary field of science focused on 
exploring and understanding the effects of chemical substances, hormones, 
and drugs on the behavior of humans and experimental animals, all with the 
final objective of understanding the neurobiological substrate of behavior and 
contributing in the development of therapeutic agents or pharmacologic tools 
for research in neurosciences [1]. The relative new popularity and accelerated 
growth of neurosciences have simultaneously led to an exponential growth on 
the scientific literature on this area that has been produced every day [2–6]. That 
makes necessary new strategies to be ready in a field that has been constantly 
actualized; for example, years ago, students with different backgrounds, who 
are graduates of psychology, medicine, or chemistry, had to study postgraduate 
trainings to specialize in the field of neurosciences. Nowadays, students from 
diverse universities can apply a career in “neurosciences” that has been recently 
designed by the National Autonomous University of Mexico few years ago [7]. 
This is an example on how universities have adapted to offer a better preparation 
on neurosciences fields. In this sense, the present book also attempts to offer the 
reader a source of current knowledge in behavioral pharmacology from different 
backgrounds.
Despite the relatively brief history of the behavioral pharmacology, it 
has significantly contributed in the understanding of the importance of the 
environmental and behavioral factors that determine the effect of drugs and 
chemical compounds with potential therapeutic and toxicological actions that 
impact on the health of the human being or another organisms [8]. In this way, 
the experimental and clinical procedures into the behavioral pharmacology have 
permitted the identification of natural or synthetic substances with potential utility 
in the treatment of central nervous system disorders, including anxiety, depression, 
and Alzheimer’s and Parkinson’s diseases [9–15], among others.
In support, the present book is a multidisciplinary compilation that illustrates 
the advancement and development of behavioral pharmacology supported 
in areas as pharmacology and psychology, experimental analysis of behavior, 
psychophysiology, and the recently called neurosciences such as neuroethology, 
neurophysiology, and neurochemistry, among others. In this book, the authors 
included and discussed results in the field of behavioral pharmacology and 
neurosciences. The chapters include scientific information derived from basic 
research in laboratory animals and the impact that this information has in the 
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development of potential pharmacological treatments to be applied in the clinical 
research to contribute in the wellness of the human being. The relevance of these 
contributions is the discussion of the experimental analysis of behavior under 
diverse pharmacological treatments, including complementary results from 
neurochemistry, neuropharmacology, neurophysiology, psychopharmacology, 
neuroanatomy, and molecular biology that permit the identification of the 
mechanism of action involved in the potential beneficial and toxic effects of the 
evaluated drugs.
2. Author’s contribution to the present book
Cueto-Escobedo and collaborators (Chapter 2) show a brief history of 
the development of behavioral pharmacology over the years, as well as the 
contribution of this science in the development of animal models that have 
contributed in the knowledge of the biological bases of behavior and importantly 
in the identification of potential therapeutic and toxic agents that may impact 
on the central nervous system disorder. Fernández-Demeneghi and collaborators 
(Chapter 3) report how identifying the potential beneficial effects of functional 
food on health has been possible through the use of the techniques of behavioral 
pharmacology. In this case they report the effects of berry juice or its secondary 
metabolites (i.e., polyphenols, anthocyanins, and other constituents) on 
some central nervous system disorders like anxiety, depression, Alzheimer’s 
and Parkinson’s diseases, and cognitive alterations. Hernandez-Lozano and 
collaborators (Chapter 4) discuss the potential use of botanical and natural 
pharmaceutical resources in the management of neuropathy pain based on 
preclinical studies. Additionally, include relevant information about of the 
phytochemical, toxicity, adverse effects, and biosecurity reported to botanical 
and natural pharmaceutical resources used in pain control.
The evaluation of natural products or new synthetic molecules with potential 
application in the treatment of symptoms that impact on the wellness of animals 
or human beings firstly may be based on exploring their effects in a traditional 
context (i.e., using extracts, infusions, or juice), but derived from these studies, 
a more specific screening is focused on isolated, characterized, and purified 
secondary metabolites, where a more controlled dosage may be realized. Garcia-
Rios and collaborators (Chapter 5) describe and discuss preclinical results of 
specific plant secondary metabolites and their potential use in clinical therapy of 
anxiety and depression, which is compared with clinically effective anxiolytic and 
antidepressant drugs. Particularly, the anxiolytic and antidepressant effects of 
terpenes, flavonoids, alkaloids, and sterols and their mechanism of action on the 
central nervous system are discussed.
Behavioral pharmacology studies also had contributed in understanding 
neurobehavioral bases that underlie some psychiatric disorders and the 
pharmacological action of drugs in a specific context. Guillen-Ruiz and 
collaborators (Chapter 6) provide a general overview of the usefulness of 
animal behavioral models to explore the anxiety disorders in childhood and 
its neurobiological bases and to then explore potential anxiolytic therapies to 
minimizing side effects in this particular population. Finally, Ocampo-Ocampo 
and collaborators (Chapter 7) address the problem of addiction and their treatment 
from behavioral analysis and an integrative holistic approach, with the aim of 
preventing or reducing the physical and mental damage that addictive substances 
may cause to the health, improving the quality of life of psychoactive substance 
consumers.
3Introductory Chapter: Behavioral Pharmacology - From Basic to Clinical Research
DOI: http://dx.doi.org/10.5772/intechopen.92446
Author details
Juan Francisco Rodríguez-Landa1,2* and Jonathan Cueto-Escobedo3
1 Laboratory of Neuropharmacology, Institute of Neuroethology, Universidad 
Veracruzana, Xalapa, Veracruz, México
2 Faculty of Biological Pharmaceutical Chemistry, Universidad Veracruzana, 
Xalapa, Veracruz, México
3 Translational and Clinical Research Department, Institute of Health Sciences, 
Universidad Veracruzana, Xalapa, Veracruz, México
*Address all correspondence to: juarodriguez@uv.mx
3. Concluding remarks
This short chapter must be considered to be a brief and necessarily incomplete 
review that has the only purpose of introducing the works of the authors in the next 
chapters to the reader. As you can see, behavioral pharmacology has brought great 
progress in the understanding of the neurobiology of different central nervous system 
disorders and in the understanding of the mechanism of action of drugs used to treat 
such disorders, as those mentioned in this chapter and the whole book. We hope the 
present work will enrich your knowledge on the study of behavioral pharmacology.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
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